StreetInsider.com News Articles

Teleflex (TFX) PT Lowered to $142 at Truist Securities

Wed, 14 Oct 2026 07:00:32 -0400

Truist Securities analyst Richard Newitter lowered the price target on Teleflex (NYSE: TFX) to $142.00 (from $150.00) while maintaining a Hold rating.

Teleflex completes enrollment in BIOMAG-LL magnesium scaffold study

Mon, 12 Oct 2026 06:30:53 -0400

Teleflex Incorporated (NYSE: TFX) has completed patient enrollment in the BIOMAG™-LL Clinical Study, which is evaluating 35 mm and 40 mm lengths of the Freesolve™ Resorbable Magnesium Scaffold (RMS) for treating coronary lesions up to 38 mm in length.

A total of 102 patients were enrolled across 14 European centers. The study is a premarket, prospective, international, multi-center, single-arm trial. Its primary endpoint is the Target Lesion Failure rate at 12 months, with clinical follow-up scheduled at 1, 6, 12, 36, and 60 months post-procedure.

The 35 mm and 40 mm scaffold lengths are also included in the ongoing BIOMAG™-III Pivotal Clinical

Teleflex completes enrollment in BIOMAG-LL magnesium scaffold study

Mon, 12 Oct 2026 06:30:53 -0400

The 35 mm and 40 mm scaffold lengths are also included in the ongoing BIOMAG™-III Pivotal Clinical

Enrollment Completed in BIOMAG™-LL Clinical Study Evaluating Longer Lengths for Freesolve™ Resorbable Magnesium Scaffold

Mon, 12 Oct 2026 06:30:00 -0400

102 patients enrolled across 14 European centers to assess safety and clinical performance of 35 mm and 40 mm Freesolve™ Resorbable Magnesium Scaffolds in long coronary lesions

WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the successful completion of patient enrollment in the BIOMAG™-LL Clinical Study, evaluating the safety and clinical performance of the Freesolve™ Resorbable Magnesium Scaffold (RMS) in 35 mm and 40 mm lengths for the treatment of de novo coronary lesions up to 38 mm. The study reflects Teleflex's commitment to expanding

Enrollment Completed in BIOMAG™-LL Clinical Study Evaluating Longer Lengths for Freesolve™ Resorbable Magnesium Scaffold

Mon, 12 Oct 2026 06:30:00 -0400

102 patients enrolled across 14 European centers to assess safety and clinical performance of 35 mm and 40 mm Freesolve™ Resorbable Magnesium Scaffolds in long coronary lesions

Teleflex study links catheter technology to 70% lower CLABSI risk

Tue, 29 Sep 2026 06:32:30 -0400

Teleflex Incorporated (NYSE: TFX) announced the publication of a peer-reviewed study in the American Journal of Infection Control showing that central venous catheters (CVCs) protected with Arrowg+ard™ Technology were associated with a 70% lower hazard of central line-associated bloodstream infections (CLABSIs) compared with plain, non-impregnated catheters over a 30-day period.

The prospective multinational study enrolled 1,750 critically ill patients across six hospitals in four countries. The hazard ratio was 0.297 (95% CI 0.134–0.658; p=0.003). Additional findings included no CLABSI events during the first five catheter days among patients receiving chlorhexidine/silver sulfadiazine (CH/SSD) CVCs, compared with 13 events in the plain CVC

Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology

Tue, 29 Sep 2026 06:30:00 -0400

Peer-reviewed publication in the American Journal of Infection Control demonstrates the use of CVCs protected with Arrowg+ard™ Technology are associated with a statistically significant and clinically meaningful reduction in the hazard of CLABSI compared with plain CVCs1.

WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters (CVCs) protected with Arrowg+ard™ Technology were associated with a statistically significant 70% lower hazard of central line-associated bloodstream infections (CLABSIs) compared with plain, non-impregnated catheters during

Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology

Tue, 29 Sep 2026 06:30:00 -0400

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Mon, 28 Sep 2026 16:30:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

Mont-Saint-Guibert, Belgium – September 28, 2026, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of Liam Kelly as Chief Executive Officer, effective October 1, 2026, succeeding Olivier Taelman.

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Mon, 28 Sep 2026 16:30:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Mon, 28 Sep 2026 16:30:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Mon, 28 Sep 2026 16:30:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Mon, 28 Sep 2026 16:30:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Mon, 28 Sep 2026 16:30:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA

BofA Securities Upgrades Teleflex (TFX) to Buy

Mon, 28 Sep 2026 07:39:21 -0400

(Updated - September 28, 2026 7:39 AM EDT)

BofA Securities analyst Craig Bijou upgraded Teleflex (NYSE: TFX) from Neutral to Buy with a price target of $158.00 (from $145.00).

The analyst comments "We upgrade TFX to Buy from Neutral and raise our PO to $158 from $145 (14x FY27E EPS vs 13x prior). We think TFX could be the next value medtech re-rating story with a new management team and better execution. We see upside to Street organic growth with 2027 being the first “clean” year. Interventional integration headwinds should be winding down and EZPLAZ could be a material Vascular growth driver.

BofA Securities Upgrades Teleflex (TFX) to Buy

Mon, 28 Sep 2026 07:39:21 -0400

(Updated - September 28, 2026 7:39 AM EDT)

BofA Securities analyst Craig Bijou upgraded Teleflex (NYSE: TFX) from Neutral to Buy with a price target of $158.00 (from $145.00).

BofA Securities Upgrades Teleflex (TFX) to Buy

Mon, 28 Sep 2026 07:39:21 -0400

(Updated - September 28, 2026 7:39 AM EDT)

BofA Securities analyst Craig Bijou upgraded Teleflex (NYSE: TFX) from Neutral to Buy with a price target of $158.00 (from $145.00).

Form 4 TELEFLEX INC For: Sep 08 Filed by: Salmon Sean

Thu, 10 Sep 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260910/27048472.html

Form 3 TELEFLEX INC For: Sep 08 Filed by: Salmon Sean

Thu, 10 Sep 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260910/27048461.html

Form 8-K TELEFLEX INC For: Sep 08

Wed, 09 Sep 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260909/27038531.html

Form SCHEDULE 13G/A TELEFLEX INC Filed by: Janus Henderson Group Ltd.

Tue, 08 Sep 2026 11:51:00 -0400

si-local-file:///var/storage/secattach/20260908/27035371.html

Teleflex adds former Medtronic cardiovascular chief to its board

Tue, 08 Sep 2026 06:31:09 -0400

Teleflex Incorporated (NYSE: TFX) has appointed Sean M. Salmon to its board of directors, effective September 8, 2026, according to a company press release.

Salmon spent more than 20 years at Medtronic plc (NYSE: MDT), most recently serving as Executive Vice President and President of its Cardiovascular Portfolio, a business with fiscal 2025 revenue of approximately $12.5 billion. He previously held leadership roles across Medtronic's Diabetes, Coronary and Structural Heart, and Coronary and Renal Denervation businesses.

Since December 2025, Salmon has operated Zamboni Holdings, LLC, a consulting and advisory firm serving venture, private equity, investment banking and strategy clients. He also serves

Teleflex adds former Medtronic cardiovascular chief to its board

Tue, 08 Sep 2026 06:31:09 -0400

Teleflex Incorporated (NYSE: TFX) has appointed Sean M. Salmon to its board of directors, effective September 8, 2026, according to a company press release.

Since December 2025, Salmon has operated Zamboni Holdings, LLC, a consulting and advisory firm serving venture, private equity, investment banking and strategy clients. He also serves

Teleflex adds former Medtronic cardiovascular chief to its board

Tue, 08 Sep 2026 06:31:09 -0400

Teleflex Incorporated (NYSE: TFX) has appointed Sean M. Salmon to its board of directors, effective September 8, 2026, according to a company press release.

Since December 2025, Salmon has operated Zamboni Holdings, LLC, a consulting and advisory firm serving venture, private equity, investment banking and strategy clients. He also serves

Teleflex adds former Medtronic cardiovascular chief to its board

Tue, 08 Sep 2026 06:31:09 -0400

Teleflex Incorporated (NYSE: TFX) has appointed Sean M. Salmon to its board of directors, effective September 8, 2026, according to a company press release.

Since December 2025, Salmon has operated Zamboni Holdings, LLC, a consulting and advisory firm serving venture, private equity, investment banking and strategy clients. He also serves